TICKERNERD
Menu
SUPNSUPNHealthcare · Drug Manufacturers - Specialty & Generic

SUPN Stock Forecast: Supernus Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$43
+0.16% on the day

The 4 Wall Street analysts covering Supernus Pharmaceuticals, Inc. hold a median 12-month price target of $63 — +45.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 6 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$2.5B
Ticker Nerd rank
80 / 100
Median analyst target
$63
Analysts covering
4
Revenue$219.1M+32.4% y/y
Operating income−$3.0M
Net income−$58.4M
Free cash flow−$5.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.6%
1M
−1.6%
YTD
−13.8%
1Y
−11.3%
From 52W high
−24.9%
From 52W low
+3.8%
$41
$57
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SUPN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Supernus Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
80 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
98
Value
96
Quality
88
Revisions
74
Accruals
68
Momentum
46
Growth
42
Issuance
38
Size
33

Volatility (98): The share price has been relatively steady.

Issuance (38): The company has been issuing shares or taking on financing, diluting existing holders.

Size (33): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SUPN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SUPN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$35$40$45$50$55$60$65$70Jan 26Apr 26Jul 26Oct 26SUPNHigh $67Median $63Low $55

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
3 Buy1 Hold0 Sell
Low $55Median $63High $67

The green dot is the last close — the median target sits +45.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 July 2026Cantor FitzgeraldMaintainsOverweight—
9 July 2026Cantor FitzgeraldMaintainsOverweight$63 → $67
19 Dec 2025StifelMaintainsHold—
29 Oct 2025B of A SecuritiesInitiatesBuy—
23 Oct 2025TD CowenMaintainsBuy—
9 Oct 2025Piper SandlerUpgradeOverweight—
30 Sept 2025Cantor FitzgeraldMaintainsOverweight—
29 Aug 2025Piper SandlerMaintainsNeutral—
6 Aug 2025Cantor FitzgeraldMaintainsOverweight—
26 Feb 2025Cantor FitzgeraldReiteratesNeutral—
19 Feb 2025Cantor FitzgeraldDowngradeNeutral—
11 Sept 2024Piper SandlerDowngradeNeutral—
28 Feb 2024Piper SandlerMaintainsOverweight—
9 Nov 2023Piper SandlerMaintainsOverweight—
25 Oct 2023Piper SandlerMaintainsOverweight—
10 May 2023Piper SandlerMaintainsOverweight—
23 Jan 2023Piper SandlerMaintainsOverweight—
31 Aug 2022Piper SandlerMaintainsOverweight—
13 Apr 2021JefferiesUpgradeBuy—
16 June 2020Piper SandlerUpgradeOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SUPN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SUPN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Supernus Pharmaceuticals, Inc. returned −11.3% against +17.3% for the S&P 500, dividends included.

SUPN vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Jan 26Apr 26Jul 26Oct 26SUPNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SUPN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−4.1%
Analysts raising
1
Analysts cutting
1
Fundamentals

Supernus Pharmaceuticals, Inc. (SUPN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
40.7×

Cheaper than 19% of US stocks

Price / sales
3.0×

Cheaper than 40% of US stocks

Price / book
2.4×

Cheaper than 38% of US stocks

EV / EBITDA
19.5×

Cheaper than 16% of US stocks

Growth & margins
Revenue growth (YoY)
32.4%

Higher than 79% of US stocks

Earnings growth (YoY)
32.4%

Higher than 67% of US stocks

Gross margin
84.6%

Higher than 94% of US stocks

Operating margin
−2.5%

Higher than 30% of US stocks

Net margin
−13.2%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−10.5%

Higher than 36% of US stocks

Return on assets
0.4%

Higher than 45% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Supernus Pharmaceuticals, Inc. (SUPN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Supernus Pharmaceuticals, Inc. has a market value of $2.5B and an enterprise value of $2.2B.

  • Revenue in the twelve months to 30 June 2026: $830.4M. The latest quarter grew 32.4% year on year.

  • Net income over the same four quarters: −$109.9M, a −13.2% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.92.

  • Free cash flow in the twelve months to 30 June 2026: $18.8M.

  • Shares outstanding: 58.2M.

  • Trailing P/E: 40.7×; forward P/E: 9.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Supernus Pharmaceuticals, Inc. employs 778 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

SUPN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
SUPNSupernus Pharmaceuticals, Inc.$2.5B
80
ALVOAlvotech$2.4B
31
LQDALiquidia Corp.$2.3B
70
PBHPrestige Consumer Healthcare, Inc.$2.2B
60
BHCBausch Health Cos., Inc.$2.2B
98
TRLVTrulieve Cannabis Corp.$2.0B
89
BCRXBioCryst Pharmaceuticals, Inc.$2.0B
88

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Supernus Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SUPN news & analysis

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

Business Wire · 24 Sept 2026neutral

Kahn Swick & Foti, LLC is investigating the proposed sale of Supernus Pharmaceuticals to Indivior Pharmaceuticals, under which Supernus shareholders would receive 1.5401 Indivior shares per Supernus share. The firm is examining the adequacy of the price and process in the proposed transaction.

Why it matters — An investigation into the adequacy of the deal's price and process could affect whether the proposed sale of Supernus to Indivior proceeds as announced.

Supernus Pharmaceuticals to Participate in September Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

Supernus Pharmaceuticals announced that its management will participate in several investor conferences scheduled for September. The biopharmaceutical company, which develops CNS treatments, will be represented at these events.

Why it matters — Investor conferences give management a platform to present the company's progress and strategy to the investment community.

Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

GlobeNewsWire · 31 Aug 2026positive

Supernus Pharmaceuticals announced that professional snowboarder Chloe Kim is partnering with the company as a compensated ambassador to discuss her ADHD diagnosis and treatment with Qelbree, a once-daily non-stimulant medication for patients aged 6 and older. Kim will share her lived experience to challenge misconceptions about ADHD and encourage others to advocate for their health and consult their doctors about potential treatment plans.

Why it matters — The high-profile ambassador partnership could raise awareness and visibility for Qelbree, Supernus' #1 prescribed branded non-stimulant ADHD treatment, potentially supporting brand awareness and patient engagement.

SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Business Wire · 29 Aug 2026negative

Halper Sadeh LLC, an investor rights law firm, announced it is investigating the proposed sale of Supernus Pharmaceuticals, Inc. to Indivior Pharmaceuticals, Inc., under which Supernus shareholders would receive 1.5401 common shares of Indivior for each Supernus share. The firm is examining whether the transaction provides a fair price to Supernus shareholders and is inviting them to learn about their rights.

Why it matters — The investigation raises questions about whether the proposed acquisition price is fair, which could affect the outcome of the deal and the value Supernus shareholders ultimately receive.

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?

Zacks Investment Research · 24 Aug 2026neutral

The news item reports that recent movements in the options market for Supernus Pharmaceuticals (SUPN) have drawn attention, raising the question of whether the options market is predicting a spike in the stock. It suggests investors need to pay close attention to SUPN based on this options activity.

Why it matters — A SUPN watcher would care because unusual options-market movements can signal shifting investor expectations about the stock's near-term price direction.

FAQ

Frequently asked questions about SUPN stock

What is the SUPN stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Supernus Pharmaceuticals, Inc. have a median 12-month price target of $63, with estimates ranging from $55 to $67. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SUPN stock a buy right now?

Of the 4 analysts covering Supernus Pharmaceuticals, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Supernus Pharmaceuticals, Inc. 80 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SUPN?

As at 6 Oct 2026, Supernus Pharmaceuticals, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).

Will SUPN stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +45.9% from the last close, and Ticker Nerd's factor model ranks Supernus Pharmaceuticals, Inc. 80 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SUPN stock forecast for 2030?

No analyst covering Supernus Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SUPN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $55 to $67 over the next 12 months.

How has SUPN stock performed over the past year?

Supernus Pharmaceuticals, Inc. returned -11.3% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Supernus Pharmaceuticals, Inc. do?

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system diseases.

What is the latest news on SUPN?

The most recent item we track (Business Wire, 24 Sept 2026): "Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN". Kahn Swick & Foti, LLC is investigating the proposed sale of Supernus Pharmaceuticals to Indivior Pharmaceuticals, under which Supernus shareholders would receive 1.5401 Indivior shares per Supernus share. The firm is examining the adequacy of the price and process in the proposed transaction.

Company

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system diseases. Supernus Pharmaceuticals, Inc. markets therapies for neurological and psychiatric conditions such as attention-deficit hyperactivity disorder, epilepsy, migraine, Parkinson’s disease-related symptoms, cervical dystonia, chronic sialorrhea, and postpartum depression. Its current portfolio includes branded medicines used in neurology and psychiatry, with products sold primarily in the United States through specialty commercial channels. The company also maintains research and development programs aimed at advancing new CNS treatments and strengthening its neuroscience portfolio. Headquartered in Rockville, Maryland, Supernus Pharmaceuticals, Inc. plays a notable role in the specialty pharmaceutical market by addressing a broad range of chronic and complex disorders affecting the central nervous system.

CEO Mr. Jack A. Khattar M.B.A. · 778 employees · United States · https://www.supernus.com